Cargando…
Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh
: World Health Organization recommends guideline for integrated management of childhood illnesses (IMCI) where Amoxicillin Dispersible Tablet (DT) appears as the first drug of choice for treating childhood pneumonia. The Government of Bangladesh adopted the IMCI strategy in 1998, and scaled it up n...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593976/ http://dx.doi.org/10.1093/eurpub/ckac129.168 |
_version_ | 1784815296901545984 |
---|---|
author | Shah, M Ahmed, S Rana, S Mothabbir, G Islam, J Islam, S |
author_facet | Shah, M Ahmed, S Rana, S Mothabbir, G Islam, J Islam, S |
author_sort | Shah, M |
collection | PubMed |
description | : World Health Organization recommends guideline for integrated management of childhood illnesses (IMCI) where Amoxicillin Dispersible Tablet (DT) appears as the first drug of choice for treating childhood pneumonia. The Government of Bangladesh adopted the IMCI strategy in 1998, and scaled it up nationwide by 2014. But, even today, the use of Amoxicillin DT, either in public or private sector, for managing childhood pneumonia is a rare event in Bangladesh. We conducted this exploratory study to understand the existing barriers, both in public and private sector, those have influences on reduced availability of Amoxicillin DT and non-compliance of health service providers to follow IMCI guideline by using Amoxicillin DT for treating a child with pneumonia, in Bangladesh. We conducted desk review of relevant strategy and policy documents, key informant interviews with 19 key individuals from Ministry of Health and national / international NGOs. Collected information were analyzed and interpreted using thematic analysis method. Identified barriers through this study pointed to inadequate policy level focus on IMCI implementation, non-inclusion of Amoxicillin DT in the national essential drug list, single source of Amoxicillin DT producing pharmaceutical in the country coupled with bureaucracy and procurement procedural complexity, lack of training of health service providers and abundant availability of antibiotic over the counter. Study respondents recommended for policy level strengthening of IMCI program, increasing coverage of training for health care provider, including practicing pediatricians both at public and private sectors, facilitating production and procurement procedures and prohibiting antibiotic sell over the counter. KEY MESSAGES: • Facilitation of production and procurement procedure coupled with enforcement of law prohibiting antibiotics availability over the counter are urgent needs. • Policy level support emphasizing full compliance of service providers for quality of implementation of IMCI program in Bangladesh (and similar other settings) is also important. |
format | Online Article Text |
id | pubmed-9593976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95939762022-11-22 Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh Shah, M Ahmed, S Rana, S Mothabbir, G Islam, J Islam, S Eur J Public Health Parallel Programme : World Health Organization recommends guideline for integrated management of childhood illnesses (IMCI) where Amoxicillin Dispersible Tablet (DT) appears as the first drug of choice for treating childhood pneumonia. The Government of Bangladesh adopted the IMCI strategy in 1998, and scaled it up nationwide by 2014. But, even today, the use of Amoxicillin DT, either in public or private sector, for managing childhood pneumonia is a rare event in Bangladesh. We conducted this exploratory study to understand the existing barriers, both in public and private sector, those have influences on reduced availability of Amoxicillin DT and non-compliance of health service providers to follow IMCI guideline by using Amoxicillin DT for treating a child with pneumonia, in Bangladesh. We conducted desk review of relevant strategy and policy documents, key informant interviews with 19 key individuals from Ministry of Health and national / international NGOs. Collected information were analyzed and interpreted using thematic analysis method. Identified barriers through this study pointed to inadequate policy level focus on IMCI implementation, non-inclusion of Amoxicillin DT in the national essential drug list, single source of Amoxicillin DT producing pharmaceutical in the country coupled with bureaucracy and procurement procedural complexity, lack of training of health service providers and abundant availability of antibiotic over the counter. Study respondents recommended for policy level strengthening of IMCI program, increasing coverage of training for health care provider, including practicing pediatricians both at public and private sectors, facilitating production and procurement procedures and prohibiting antibiotic sell over the counter. KEY MESSAGES: • Facilitation of production and procurement procedure coupled with enforcement of law prohibiting antibiotics availability over the counter are urgent needs. • Policy level support emphasizing full compliance of service providers for quality of implementation of IMCI program in Bangladesh (and similar other settings) is also important. Oxford University Press 2022-10-25 /pmc/articles/PMC9593976/ http://dx.doi.org/10.1093/eurpub/ckac129.168 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Parallel Programme Shah, M Ahmed, S Rana, S Mothabbir, G Islam, J Islam, S Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh |
title | Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh |
title_full | Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh |
title_fullStr | Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh |
title_full_unstemmed | Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh |
title_short | Barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in Bangladesh |
title_sort | barriers for using amoxycillin dispersible tablet in pediatric pneumonia treatment in bangladesh |
topic | Parallel Programme |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593976/ http://dx.doi.org/10.1093/eurpub/ckac129.168 |
work_keys_str_mv | AT shahm barriersforusingamoxycillindispersibletabletinpediatricpneumoniatreatmentinbangladesh AT ahmeds barriersforusingamoxycillindispersibletabletinpediatricpneumoniatreatmentinbangladesh AT ranas barriersforusingamoxycillindispersibletabletinpediatricpneumoniatreatmentinbangladesh AT mothabbirg barriersforusingamoxycillindispersibletabletinpediatricpneumoniatreatmentinbangladesh AT islamj barriersforusingamoxycillindispersibletabletinpediatricpneumoniatreatmentinbangladesh AT islams barriersforusingamoxycillindispersibletabletinpediatricpneumoniatreatmentinbangladesh |